Validated UV Spectrophotometric Methods for the Estimation of Letrozole in Solid Dosage Forms
DOI:
https://doi.org/10.37285/ijpsn.2018.11.3.7Abstract
The main intent of this research is to develop two new simple, novel, cost efficient and precise UV spectrophotometric methods for estimation of letrozole in pure and pharmaceutical dosage forms. For estimation of letrozole based on the measurement of UV light absorption, the spectras of letrozole were scanned efficiently and it exhibits maximum absorption wavelength (λmax) at 240nm for Method A and 245nm for Method B. The analysis was carried out against phosphate buffer pH 6.8 (Method A) and phosphate buffer pH 3.8 (Method B) respectively. The drug shows linear response commencing from 0.5-20 µg/mL for both methods A & B. The regression equation was found as Y= 0.099X + 0.079 (Method A) and Y= 0.1359x + 0.0048 (Method B), and correlation coefficient were 0.999 (Method A) and 0.9999 (Method B). The method validation was accomplished as per the regulation of ICH Q2R1 guidelines for linearity, accuracy, and precision studies. These reported methods have good reproducibility with percentage RSD less than one. These methods were extended towards the formulation and there was no interruption from excipients in the formulation. Hence, these proposed methods can be effectively employed for evaluation of letrozole in quality control as well as routine analysis work in pharmaceutical industries.
Downloads
Metrics
Keywords:
UV-spectrophotometry, Methanol, Validation, Precision, Optical characteristicS, Accuracy
Downloads
Published
How to Cite
Issue
Section
References
Bhatnagar AS, Batzl C, Hausler A, Schieweck K, Lang M and Trunet PF (1996). Pharmacology of nonsteroidal aromatase inhibitors: In: (Pasqualini JR, Katzenellenbogen BS eds), Hormonedependent cancer. Marcel Dekker, New York, pp 155.
Bhatnagar AS, Hausler A, Schieweck K, Lang M and Bowman R (1990). Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem Mol Biol 7: 1021-1027.
Bhatnagar AS (2007). The discovery and mechanism of action of letrozole. Breast Cancer Res Tr 105 (Suppl 1): 7-17.
Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ and McHugh M (2008). Letrozole suppress plasma oestradiol (E2) levels more completely in postmenopausal women with breast cancer. J Clin Oncol 26: 1671-1676.
Geisler J, Haynes B, Anker G, Dowsett M and Lonning PE (2002). Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study. J Clin Oncol 20: 751-757.
ICH Guidelines Q2 (R1) (2005). “Validation of analytical procedures: text and methodology,” in ICH Harmonized Tripartite Guidelines.
ICH Q2B (2005). “Validation of Analytical Procedures: Methodology, adopted in 1996, Geneva Q2B, incorporated in Q2 (R1).
International conference on Harmonization Guidance for Industry In (1994). Q2A Text on Validation of Analytical Methods, Switzerland: IFPMA; pp 1-4.
International conference on Harmonization, Guidance for Industry In (1996). Q2B Validation of Analytical Procedures, Methodology, Switzerland: IFPMA; pp 1-8.
Iyer S, Validation of analytical Procedure: Guidelines on CGMP and Quality of Pharmaceutical Products. D K Publications, Chapter-8, pp 145-150.
Laha TK, Patnaik RK and Sen S (2008). Reverse phase high performance liquid chromatographic method for the analysis of Letrozole in pharmaceutical dosage forms. Indian J Pharm Sci 70: 401-403.
Lamb HM and Adkins JC (1998). Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 56: 1125-1140.
Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M and Brodie A (1999). The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Rel Treat 57: 183-192.
Methodology. ICH Harmonised Tripartite Guideline (2005). “Validation of analytical procedures” Having reached Step 4 of the ICH Process. ICH Steering Committee Meeting: Nov. 6.
Miller WR (1999). Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast. Endocr Rela Cancer 6: 187-195.
Ping GU, Yura LI and Yuxia WU (2001). Determination of related substances in letrozole and its Tablets by TLC and HPLC. Chinese J Pharmaceuticals 7: 317-318.
Scott LJ and Keam SJ (2006). Letrozole: in postmenopausal hormone-responsive early-stage breast cancer. Drugs 66. 3: 353-362.
Sekar V, Jayaseelan S, Subash N, Udhaya kumar E, Perumal P and Venkatesh RP (2009). Bioanalytical method development and validation of letrozole by RP-HPLC method. Int J Pharm Res Dev 1: 1-7.
The Merck Index (2001). An Encyclopaedia of Chemicals, Drugs and Biologicals, 13th ed. Merk & co., Inc., pp 974.
The United State Pharmacopoeia 24 (2000). The National Formulary 19; Chapter-1225, Validation of compendial methods.
Torrisi R, Rota S, Losurdo A, Zuradelli M, Masci G and Santoro A (2016). Aromatase inhibitors in premenopause: Great expectations fulfilled. Crit Rev Oncol Hematol 107: 82-89.
U.S. FDA. Guidance for Industry (draft): (2000). Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls and Documentation.
USP 30. The United States Pharmacopoeia (2007). United States, Pharmacopeial Convention, 29th ed. Rockville, pp 680-683.
Zarghi A, Foroutan SM, Shafaati A and Khoddam A (2007). HPLC determination of letrozole in plasma using fluorescence detection: Application to pharmacokinetic studies. Chromatographia 66: 747-750.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf
http://www.scinopharm.com/Drug profile/Letrozole
https://www.slideshare.net/NailaKanwal/ich-q2-analytical-method-validation
http://shodhganga.inflibnet.ac.in/bitstream/10603/8513/9/09_chapter%202.pdf
www.fda.gov/ohrms/dockets/ac/02/slides/3841s1_07_lachman. PPT
